reason report
pt
bottom line reiter op increas
estim follow impress sales/ep beat procedur
growth handili top consensu ww system
placement came vs consensu upsid prompt
management bump low-end procedur outlook
think still set beat rais
rest year continu see multipl avenu estim
upsid new product cycl begin unfold sp flex cathet
robot compani drive increas penetration/ accept
grow set intern market new us gen surgeri
procedur area dcf base pt goe higher
high qualiti way kick upsid across board --
system procedur margin revenue ep came ahead
expect report revenue compar
consensu out-performance driven
system instrument accessori servic revenu
line beat driven better-than-expect system revenue
versu consensu lp estimate
accessori revenue also contribut beat versu consensu come
versu lp estimate gm
beat consensu adj ebita mgn vs
con demonstr y/i oper leverag ep beat
street
midpoint log ww procedur growth reflect
upsid vs consensu reflect steadi comp adj y/i growth
procedur growth ex sell day us grew fuel continu
momentum emerg us surgeri well anoth qtr better-
than-expect urolog gyn trend ou y/i procedur growth
line estimate saw sell day headwind
well neg impact time china growth moder
expect capac expans depend quota
govern add new system still wait management rais midpoint
guidanc qtr prior vs
strong top-lin beat think rang conserv
got toughest comp year momentum driver appear
intact new procedur slightli midpoint
compani inform leerink partner llc research
revenu mm ep ex item stock expens defer revenu amort
ep adjust stock split
medic suppli devic
dcf wgtd average cost
net debt total capit
price-to-earnings lt ep growth
pleas refer page import disclosur price chart analyst certif
across geographi us system
compar estimate consensu meaning
out-performance come xi vs forecast compani
continu place higher system oper leas
well total system last two quarter management note
system place ww xi ou system
line consensu lp estimate thirty-on percent system
placement involv trade-in quarter
indic custom prefer newer tech
back fda sp follow submiss
process prepar respons approv still
track model sp sale start lp unit
compani also receiv respons fda
submiss relat stapler also like track
launch flexibl cathet robot platform lung biopsi management
anticip submiss estimate revenue contribut
includ approv us china europ model
revenu respect japan
benefit go forward new recent da vinci procedur approv
though management continu emphas adopt gradual
requir market invest nonetheless increas
confid potenti sustain procedur growth
beyond
model updat rev/ep increas reflect upsid
sales/ep increas reflect upsid slightli
aggress system placement procedur growth assumpt
project procedur growth model ww system
placement year includ sp unit continu model
op-ex growth consist management guidanc rang
new sales/ep also increas sit
y/i respect
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan new product cycl
 xi sp flexibl cathet robot help sustain above-averag top- bottom-lin
double-digit growth system advanc continu open increment surgery/revenu
sourc time near-to-intermedi term continu see multipl avenu
drive estim upsid new product cycl gradual unfold sp lung biopsi
compani drive increas penetration/accept grow set intern market
valuat base dcf analysi yield pt discount rate
calcul use capm model price-to-earnings basi pt translat
cash ep respect current trade ex-cash
basi incl cash ex-cash incl cash vs broader market
cap med-tech average believ isrg premium group sustain given
help drive increas penetr still-larg under-penetrated long-term
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota
newer robot entrant mdt/jnj beyond come onto scene
result competit trial potenti caus hospit purchas cycl elong given
robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term earn
power -- -v weve model
dollar million except ep
revenu
compani report streetaccount leerink partner llc estim
dollar million
estimate
estimate
compani report streetaccount leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior
period tabl present financi result restat reflect effect adopt
dollar million except ep
revenu
compani report leerink partner llc estim pro-forma exclud def revenue sbc amort
intuit surgic estim chang revenu
dollar million
compani report leerink partner llc estim
compani report leerink partner llc estim
dollar million except per share data
good sold
pre-split dilut averag share million
post-split dilut averag share million
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect adopt
dollar million except per share data
total
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect adopt
